More Companies Tapping Direct Sales Route In China
This article was originally published in PharmAsia News
Under the influence of a changing policy environment, China's healthcare companies are experiencing a development bottleneck. The need to upgrade to new business models and finding new ways of doing so have become realities for many companies, and more and more are tapping into the opportunities presented by direct sales, including A-share market-listed and state-owned companies.
You may also be interested in...
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.
Oncologie acquires PS-targeting candidate bavituximab, which may help other cancer therapies in attacking tumors. BridgeBio's newest spinout will develop former Novartis cancer candidate infigratinib.
Strongbridge obtains rights from AEterna Zentaris to first drug approved for adult growth hormone deficiency. While the J.P. Morgan Healthcare Conference didn't have many major deal announcements, there was a flurry of announcements around discovery and development capabilities.